- Home
- SITC vs ABOS Comparison
SITC vs ABOS Comparison
Compare SITC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | ABOS |
|---|---|---|
| Founded | 1965 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 165.6M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SITC | ABOS |
|---|---|---|
| Price | $0.68 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 4.0M | ★ 5.2M |
| Earning Date | 11-02-2026 | 10-26-2026 |
| Dividend Yield | ★ 590.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,649,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.19 |
| 52 Week High | $7.49 | $3.60 |
Technical Indicators
Market Signals| Indicator | SITC | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 12.64 | 21.23 |
| Support Level | N/A | $0.19 |
| Resistance Level | $3.74 | $2.56 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.37 | -0.08 |
| Stochastic Oscillator | 2.65 | 1.43 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.